Soleno Therapeutics (SLNO) Operating Leases (2021 - 2026)

Soleno Therapeutics (SLNO) has 6 years of Operating Leases data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 33.33% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 33.33% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, down 21.44% from the prior year.
• Operating Leases for Q1 2026 stood at $3.2 million, up from $2.0 million in the prior quarter.
• Over the last five years, Operating Leases for SLNO reached as high as $3.2 million in Q1 2026 and fell as low as $37000.0 in Q1 2024.
• Historically, Operating Leases has averaged $1.5 million across 5 years, with a median of $2.0 million in 2025.
• On a YoY basis, Operating Leases climbed as much as 6386.49% in 2025 and fell as far as 21.44% in 2025.
• Year by year, Operating Leases stood at $79000.0 in 2022, then increased by 26.58% to $100000.0 in 2023, then soared by 2400.0% to $2.5 million in 2024, then declined by 21.44% to $2.0 million in 2025, then jumped by 62.93% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $3.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.